Company profile for Spirovant Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Spirovant Sciences, a biotechnology company located in Philadelphia, is a leader in the development of gene therapies for cystic fibrosis (CF) and other lung diseases. Spirovant is focused on changing the course of cystic fibrosis and other pulmonary diseases. Our gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis. Spirovant has develo...
Spirovant Sciences, a biotechnology company located in Philadelphia, is a leader in the development of gene therapies for cystic fibrosis (CF) and other lung diseases. Spirovant is focused on changing the course of cystic fibrosis and other pulmonary diseases. Our gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis. Spirovant has developed a number of innovations in multiple viral vectors that collectively have the potential to overcome challenges that have previously limited the clinical viability of gene therapy for cystic fibrosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3675 Market Street, Suite 200 Philadelphia, PA 19104
Telephone
Telephone
(267) 244-8206
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/spirovant-launches-state-of-the-art-laboratory-and-headquarters-301547540.html

PRNEWSWIRE
16 May 2022

https://www.prnewswire.com/news-releases/spirovant-presents-preclinical-data-showing-sp-101-restores-cf-transmembrane-conductance-regulator-function-at-the-2021-north-american-cystic-fibrosis-conference-301416891.html

PRNEWSWIRE
04 Nov 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty